Generate Biomedicines GENB
$9.54 −$0.83 (-8.00%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $9.90 +3.77%
Open$10.06
Prev close$10.37
Day range$9.40 – $10.58
Volume967.9K
Market cap$1.23B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$4.22M-56.2% YoY
Operating profit-$91.51M-45.7% YoY
Net profit-$87.66M-46.0% YoY
Diluted EPS-$0.68-32.9% YoY
Free cash flow-$57.01M-17.2% YoY
Operating cash flow-$54.86M
Revenue, last 7 quarters
Net profit, last 7 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Operating margin-1,382.0%
Net margin-1,381.8%
Return on equity-76.4%
Return on assets-56.4%
Return on invested capital-65.5%
Current ratio5.01
Liabilities / assets26.1%
Cash & investments$404.21M
Total debt$52.01M
Net cash (debt)$352.20M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Pretax Profit | -$87.61M | -$67.20M | -$61.69M | -$61.85M | -$222.80M |
| Total Operating Revenue | $4.22M | $6.31M | $7.22M | $3.31M | $31.89M |
| Total Revenue as Reported | $4.22M | $6.31M | $7.22M | $3.31M | $31.89M |
| Basic EPS | -$0.68 | -$0.52 | -$1.07 | -$0.53 | -$2.18 |
| Operating Expense | $95.73M | $77.93M | $71.34M | $67.26M | $266.96M |
| Selling and Admin Expenses | $13.47M | $13.60M | $13.52M | $11.27M | $42.26M |
| Gain on Sale of Security | -$58,000.00 | -$62,000.00 | -$305,000.00 | -$176,000.00 | -$262,000.00 |
| Other Income (Expense) | -$58,000.00 | -$62,000.00 | -$305,000.00 | -$176,000.00 | -$262,000.00 |
| Non-Operating Interest Expense | $192,000.00 | $155,000.00 | $182,000.00 | $208,000.00 | $1.14M |
| Non-Operating Interest Income | $4.15M | $4.63M | $2.91M | $2.49M | $13.66M |
| Net Non-Operating Interest Income (Expense) | $3.96M | $4.47M | $2.73M | $2.28M | $12.53M |
| Operating Profit | -$91.51M | -$71.61M | -$64.11M | -$63.95M | -$235.07M |
| Research & Development | $82.25M | $64.33M | $57.81M | $55.99M | $224.70M |
| -General & Admin Expense | $13.47M | $13.60M | $13.52M | $11.27M | $42.26M |
| Net Profit | -$87.66M | -$67.26M | -$61.71M | -$61.88M | -$222.97M |
| Diluted EPS | -$0.68 | -$0.52 | -$1.07 | -$0.53 | -$2.18 |
| Net Income to Common Stockholders | -$87.66M | -$67.26M | -$69.20M | -$67.02M | -$249.52M |
| Net Income to Parent Company | -$87.66M | -$67.26M | -$61.45M | -$55.43M | -$203.15M |
| Minority Interests | $0.00 | $0.00 | -$268,000.00 | -$6.45M | -$19.81M |
| Profit from Continuing Operations | -$87.66M | -$67.26M | -$61.71M | -$61.88M | -$222.97M |
| Tax | $49,000.00 | $53,000.00 | $28,000.00 | $29,000.00 | $163,000.00 |
| Preferred Stock Dividends | – | – | $7.75M | $11.59M | $46.37M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$54.86M | -$57.94M | -$80.39M | -$200.62M | -$50.26M |
| Net cash flow from continuing operations | -$54.86M | -$57.94M | -$80.39M | -$200.62M | -$50.26M |
| Net Income from Continuing Operations | -$87.66M | -$67.26M | -$61.71M | -$222.97M | -$61.88M |
| Gain/Loss from Continuing Operations | $0.00 | $0.00 | $363,000.00 | $49,000.00 | – |
| Depreciation & Depletion & Amortization | $3.69M | $3.22M | $3.27M | $13.18M | $3.13M |
| Other Non-Cash Items | $4.78M | $2.69M | $2.09M | $5.94M | $3.99M |
| Change in Working Capital | $16.72M | -$4.46M | -$30.65M | -$14.62M | -$705,000.00 |
| -Change in Receivables | $0.00 | $0.00 | $0.00 | $308,000.00 | $445,000.00 |
| Net Issuance Payments Of Debt | -$1.36M | -$993,000.00 | -$1.12M | -$8.16M | -$1.31M |
| Net Common Stock Issuance | $0.00 | $0.00 | $369.29M | – | – |
| Net Preferred Stock Issuance | $0.00 | $0.00 | $0.00 | $21.97M | $0.00 |
| Proceeds from Stock Option Exercised | $4.84M | $414,000.00 | $3.22M | $1.10M | $388,000.00 |
| Net Other Financing Charges | $0.00 | $0.00 | $7.50M | $13.15M | $4.90M |
| Ending Cash Balance | $144.38M | $139.39M | $164.61M | $126.04M | $126.04M |
| Net Change in Cash | $4.99M | -$25.21M | $38.57M | -$55.79M | $2.83M |
| Beginning Cash Balance | $139.39M | $164.61M | $126.04M | $181.83M | $123.20M |
| Net Cash Flow from Continuing Financing Activities | $3.49M | -$579,000.00 | $378.89M | $28.06M | $3.98M |
| Financing Cash Flow | $3.49M | -$579,000.00 | $378.89M | $28.06M | $3.98M |
| -Change in Prepaid Assets | $2.41M | $5.91M | -$6.22M | -$166,000.00 | $398,000.00 |
| -Change in Payables and Accrued Expense | $21.88M | $2.21M | -$17.30M | $15.24M | $5.13M |
| -Change in Other Current Assets | -$283,000.00 | -$4.31M | $2.05M | $4.84M | $388,000.00 |
| -Change in Other Current Liabilities | -$3.07M | -$1.95M | -$1.96M | -$2.94M | -$3.75M |
| -Change In Other Working Capital | -$4.22M | -$6.31M | -$7.22M | -$31.89M | -$3.31M |
| Net cash flow from investing | $56.36M | $33.31M | -$259.93M | $116.77M | $49.12M |
| Net Cash Flow from Continuing Investing Activities | $56.36M | $33.31M | -$259.93M | $116.77M | $49.12M |
| Net Investment Purchase and Sale | $58.51M | $34.24M | -$256.15M | $120.28M | $51.49M |
| Free Cash Flow | -$57.01M | -$58.88M | -$84.17M | -$204.13M | -$52.64M |
| Net PPE Purchase and Sale | -$2.16M | -$933,000.00 | -$3.78M | -$3.51M | -$2.37M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Total Non-Current Assets | $101.25M | $91.44M | $90.35M | $95.82M | $95.82M |
| Total Liabilities | $134.73M | $105.65M | $110.94M | $953.38M | $953.38M |
| Total Current Liabilities | $82.72M | $56.64M | $58.39M | $82.20M | $82.20M |
| Payables | $7.89M | $5.65M | $7.62M | $3.84M | $3.84M |
| -Accounts Payable | $7.89M | $5.65M | $7.62M | $3.84M | $3.84M |
| Current Accrued Expenses | $29.37M | $14.70M | $12.50M | $25.74M | $25.74M |
| Short-Term Debt and Capital Lease Obligation | $23.33M | $13.62M | $14.26M | $15.01M | $15.01M |
| -Current Capital Lease Obligation | $23.33M | $13.62M | $14.26M | $15.01M | $15.01M |
| Current Deferred Liabilities | $7.95M | $12.17M | $17.24M | $21.19M | $21.19M |
| Other Non-Current Assets | $9.34M | $9.06M | $4.75M | $6.81M | $6.81M |
| -Accumulated Depreciation | -$58.45M | -$54.75M | -$51.53M | -$48.26M | -$48.26M |
| Other Current Assets | $10.43M | $12.84M | $18.75M | $12.53M | $12.53M |
| Restricted Cash | $0.00 | $0.00 | $0.00 | $339,000.00 | $339,000.00 |
| -Short Term Investments | $263.86M | $322.06M | $356.07M | $99.85M | $99.85M |
| -Cash and Cash Equivalents | $140.35M | $135.36M | $160.58M | $121.65M | $121.65M |
| Cash and Cash Equivalents & Short-Term Investments | $404.21M | $457.42M | $516.64M | $221.50M | $221.50M |
| Total Current Assets | $414.64M | $470.25M | $535.39M | $234.37M | $234.37M |
| Total Assets | $515.89M | $561.69M | $625.74M | $330.18M | $330.18M |
| -Gross PPE | $150.36M | $137.13M | $137.13M | $137.27M | $137.27M |
| Other Current Liabilities | $3.16M | $2.52M | $2.42M | $2.63M | $2.63M |
| Total Non-Current Liabilities | $52.01M | $49.01M | $52.55M | $871.18M | $871.18M |
| Long Term Debt and Capital Lease Obligation | $52.01M | $49.01M | $51.31M | $53.52M | $53.52M |
| Gains/Losses Not Affecting Retained Earnings | -$264,000.00 | -$129,000.00 | $24,000.00 | $106,000.00 | $106,000.00 |
| Minority Interests | $0.00 | $0.00 | $0.00 | -$7.23M | -$7.23M |
| Net PPE | $91.91M | $82.38M | $85.60M | $89.01M | $89.01M |
| Retained Earnings | -$892.65M | -$804.99M | -$737.74M | -$676.29M | -$676.29M |
| Additional Paid-In Capital | $1.27B | $1.26B | $1.25B | $60.19M | $60.19M |
| -Long Term Capital Lease Obligation | $52.01M | $49.01M | $51.31M | $53.52M | $53.52M |
| Derivative Product Liabilities | $0.00 | $0.00 | $0.00 | $1.21M | $1.21M |
| Non-Current Deferred Liabilities | $0.00 | $0.00 | $1.24M | $4.51M | $4.51M |
| Convertible preferred securities | $0.00 | $0.00 | $0.00 | $811.83M | $811.83M |
| Total Equity | $381.16M | $456.05M | $514.80M | -$623.20M | -$623.20M |
| Stockholders' Equity | $381.16M | $456.05M | $514.80M | -$615.97M | -$615.97M |
| Capital Stock | $129,000.00 | $128,000.00 | $128,000.00 | $33,000.00 | $33,000.00 |
| -Common Stock | $129,000.00 | $128,000.00 | $128,000.00 | $33,000.00 | $33,000.00 |
| -Accounts Receivable | – | – | – | $0.00 | $0.00 |
| Other Non-Current Liabilities | – | – | – | $116,000.00 | $116,000.00 |
| Receivables | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on GENB.
Sign in to join the discussion.